IBRANCE Drug Patent Profile

When do Ibrance patents expire, and when can generic versions of Ibrance launch?

Ibrance is a drug marketed by Pfizer and is included in two NDAs. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and sixty-nine patent family members in fifty-six countries.

The generic ingredient in IBRANCE is palbociclib. There are thirteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the palbociclib profile page.

DrugPatentWatch^® Generic Entry Outlook for Ibrance

Ibrance was eligible for patent challenges on February 3, 2019.

There have been thirty-eight patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are seven tentative approvals for the generic drug (palbociclib), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for IBRANCE

International Patents:	169
US Patents:	3
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	128
Patent Applications:	4,925
Drug Prices:	Drug price information for IBRANCE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for IBRANCE
What excipients (inactive ingredients) are in IBRANCE?	IBRANCE excipients list
DailyMed Link:	IBRANCE at DailyMed

See drug prices for IBRANCE

Recent Clinical Trials for IBRANCE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Medical Center Groningen	Phase 4
Megalabs	PHASE4
AstraZeneca	Phase 1/Phase 2

See all IBRANCE clinical trials

Pharmacology for IBRANCE

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 3A Inhibitors Kinase Inhibitors

Paragraph IV (Patent) Challenges for IBRANCE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IBRANCE	Tablets	palbociclib	75 mg, 100 mg and 125 mg	212436	1	2020-11-24
IBRANCE	Capsules	palbociclib	75 mg, 100 mg and 125 mg	207103	12	2019-02-04

US Patents and Regulatory Information for IBRANCE

IBRANCE is protected by three US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-001	Feb 3, 2015		RX	Yes	No	RE47739*PED				Y
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-002	Nov 1, 2019		RX	Yes	No	RE47739*PED				Y
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-003	Nov 1, 2019		RX	Yes	Yes	10,723,730*PED				Y
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-002	Feb 3, 2015		RX	Yes	No
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-001	Feb 3, 2015		RX	Yes	No
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-003	Feb 3, 2015		RX	Yes	Yes
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-002	Nov 1, 2019		RX	Yes	No	11,065,250*PED				Y

Expired US Patents for IBRANCE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-002	Nov 1, 2019	7,456,168
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-001	Feb 3, 2015	6,936,612
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-003	Feb 3, 2015	6,936,612
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-002	Feb 3, 2015	6,936,612
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-003	Feb 3, 2015	7,456,168
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-002	Feb 3, 2015	7,456,168
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-002	Nov 1, 2019	6,936,612

EU/EMA Drug Approvals for IBRANCE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Europe MA EEIG	Ibrance	palbociclib	EMEA/H/C/003853Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer:in combination with an aromatase inhibitor;in combination with fulvestrant in women who have received prior endocrine therapy.In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.	Authorised	no	no	no	2016-11-09

International Patents for IBRANCE

When does loss-of-exclusivity occur for IBRANCE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

New Zealand

Peru

Poland

Portugal

Russian Federation

Saudi Arabia

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Turkey

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IBRANCE around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2764459
Singapore	11201505680R
Cyprus	1122454
Hong Kong	1211032
Japan	2005519909
Australia	2003237009
South Korea	20040077759

Supplementary Protection Certificates for IBRANCE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1470124	614	Finland
1470124	1790011-9	Sweden		PRODUCT NAME: PALBOCICLIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/16/1147 20161111
1470124	300863	Netherlands		PRODUCT NAME: PALBOCICLIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/16/1147 20161111
1470124	PA2017013,C1470124	Lithuania		PRODUCT NAME: PALBOCIKLIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS PAVIDALU; REGISTRATION NO/DATE: EU/1/16/1147 20161109
1470124	17C1012	France		PRODUCT NAME: PALBOCICLIB, ET TOUTES SES FORMES RELEVANT DE LA PROTECTION DU BREVET DE BASE.; REGISTRATION NO/DATE: EU/1/16/1147 20161109
1470124	2017/009	Ireland		PRODUCT NAME: PALBOCICLIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESTER, AMIDE OR PRODRUG THEREOF; REGISTRATION NO/DATE: EU/1/16/1147/001 EU/1/16/1147/006 20161109
1470124	C20170012 00212	Estonia		PRODUCT NAME: PALBOTSIKLIIB;REG NO/DATE: EU/1/16/1147 11.11.2016

IBRANCE Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

This report analyzes the market dynamics and financial trajectory of IBRANCE (palbociclib), a CDK4/6 inhibitor. The analysis focuses on patent landscape, regulatory approvals, market access, competitive positioning, and financial performance, drawing on publicly available data.

What is IBRANCE and its Mechanism of Action?

IBRANCE is an orally administered small molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6. CDK4 and CDK6 are key regulators of the cell cycle, promoting progression through the G1 phase. In estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer, dysregulation of the G1 to S phase transition is a common event. Inhibition of CDK4/6 by IBRANCE in combination with an aromatase inhibitor or fulvestrant is approved to treat postmenopausal women with ER+/HER2- advanced or metastatic breast cancer as initial endocrine-based therapy or after disease progression following endocrine therapy.

What is the Patent Landscape for IBRANCE?

The patent landscape for IBRANCE is a critical factor in its market exclusivity and financial performance. Pfizer, the developer, holds a portfolio of patents covering the compound, its formulations, and methods of use.

• Core Compound Patents: The primary patents protecting the active pharmaceutical ingredient (API), palbociclib, have provided foundational exclusivity.
• Formulation Patents: Additional patents cover specific formulations designed to enhance stability, bioavailability, or patient convenience.
• Method of Use Patents: Patents relating to specific treatment regimens, combinations with other therapies, and indications have extended market protection.

The expiration of key patents will open the door for generic competition, significantly impacting IBRANCE's market share and revenue. Detailed analysis of patent expiry dates, including any potential patent extensions or litigation outcomes, is crucial for forecasting future market dynamics. For instance, the U.S. Patent and Trademark Office (USPTO) has granted patents covering palbociclib, with expiry dates generally extending into the late 2020s and early 2030s, though specific litigation and post-grant reviews can alter these timelines.

What are the Key Regulatory Approvals for IBRANCE?

Regulatory approvals by major health authorities are essential for market access and commercialization.

• United States (FDA): IBRANCE received its first U.S. Food and Drug Administration (FDA) approval on February 3, 2015, in combination with letrozole for postmenopausal women with ER+/HER2- advanced or metastatic breast cancer as initial endocrine therapy. Subsequent approvals expanded its use:
  • February 2015: Initial approval with letrozole for postmenopausal women with ER+/HER2- advanced or metastatic breast cancer who have not received prior endocrine therapy.
  • February 2016: Approved in combination with fulvestrant for postmenopausal women with ER+/HER2- advanced or metastatic breast cancer, following disease progression on prior endocrine therapy.
  • July 2020: Expanded indication to include men with ER+/HER2- advanced or metastatic breast cancer, in combination with endocrine therapy.
• European Union (EMA): The European Medicines Agency (EMA) granted marketing authorization for IBRANCE in June 2015, in combination with an aromatase inhibitor or fulvestrant.
• Other Jurisdictions: IBRANCE has received approvals in numerous other countries, including Canada, Japan, Australia, and various nations in Latin America and Asia, with varying dates and approved indications.

The comprehensive regulatory approvals in major markets have facilitated IBRANCE's global commercialization.

What is the Market Access and Pricing Strategy for IBRANCE?

Market access and pricing are critical determinants of a drug's commercial success.

• Indication Expansion: Pfizer has strategically pursued regulatory approvals for IBRANCE in expanded patient populations and treatment settings, thereby increasing its addressable market.
• Combination Therapy Focus: The approved use of IBRANCE in combination with other endocrine agents (aromatase inhibitors like letrozole, or fulvestrant) has been a cornerstone of its market positioning, offering a therapeutic advantage over monotherapy in its approved indications.
• Pricing: As a novel oncology therapeutic, IBRANCE was launched at a premium price. List prices are typically in the range of \$10,000 to \$15,000 per month in the U.S., before rebates and discounts. Net prices after payer negotiations are lower, but still reflect the value proposition of the drug in advanced breast cancer.
• Payer Negotiations: Pfizer has engaged in extensive negotiations with payers and pharmacy benefit managers (PBMs) to secure formulary placement and favorable reimbursement terms. This involves demonstrating clinical and economic value, often through health technology assessments and cost-effectiveness analyses.
• Patient Assistance Programs: Programs are in place to mitigate out-of-pocket costs for eligible patients, enhancing access and adherence.

The pricing and market access strategy has been designed to maximize revenue while ensuring broad patient eligibility and uptake.

What is the Competitive Landscape for IBRANCE?

The CDK4/6 inhibitor class has become a significant area of competition in the ER+/HER2- metastatic breast cancer market.

• Direct Competitors (CDK4/6 Inhibitors):
  • Verzenio (abemaciclib) by Eli Lilly: Approved in the U.S. in 2017. Verzenio has gained significant market share, particularly in later lines of therapy and with demonstrated improvements in overall survival in certain patient populations. It is approved for both HR+/HER2- advanced/metastatic breast cancer and early-stage breast cancer.
  • Kisqali (ribociclib) by Novartis: Approved in the U.S. in 2017. Kisqali has also established a strong market presence, with clinical trials demonstrating improvements in progression-free survival (PFS) and overall survival (OS) when used in combination with endocrine therapy. It is approved for both first-line and later-line HR+/HER2- metastatic breast cancer, and for early-stage HR+/HER2- breast cancer.
• Other Endocrine Therapies: IBRANCE competes indirectly with other endocrine agents and targeted therapies used in breast cancer treatment, particularly in earlier lines of therapy where treatment decisions are complex.
• Emerging Therapies: Research and development continue for novel agents in breast cancer, including other targeted therapies and immunotherapies, which may impact the long-term competitive landscape.

The competitive intensity has increased significantly since IBRANCE's launch, requiring ongoing differentiation through clinical data and market access efforts.

What is the Financial Performance of IBRANCE?

IBRANCE has been a major revenue driver for Pfizer since its launch.

• Revenue Growth: IBRANCE demonstrated rapid revenue growth in its initial years, driven by strong clinical data, early FDA approval, and broad uptake by oncologists.
  • 2015: \$777 million
  • 2016: \$2.1 billion
  • 2017: \$3.1 billion
  • 2018: \$4.0 billion
  • 2019: \$4.7 billion
  • 2020: \$5.4 billion
  • 2021: \$5.4 billion
  • 2022: \$5.1 billion
  • 2023: \$4.9 billion
• Peak Sales: IBRANCE achieved peak annual sales of approximately \$5.4 billion in 2020 and 2021.
• Revenue Decline Post-Peak: The slight decline in revenue observed in 2022 and 2023 reflects the increasing competitive pressure from Verzenio and Kisqali, as well as potential shifts in treatment paradigms and the approach of patent expiries in key markets.
• Contribution to Pfizer's Portfolio: For several years, IBRANCE was one of Pfizer's leading products, significantly contributing to the company's overall revenue and profitability. Its performance has been instrumental in funding further R&D and acquisitions.

The financial trajectory highlights the immense commercial success of IBRANCE, while also indicating the natural lifecycle pressures faced by blockbuster drugs due to competition and patent cliffs.

What are the Future Market Projections for IBRANCE?

The future market trajectory for IBRANCE will be shaped by several key factors:

• Generic Competition: The most significant threat to IBRANCE's market share and revenue is the impending expiry of its key patents, which will allow for the introduction of generic versions of palbociclib. Generic entry in the U.S. is anticipated as early as late 2027 or 2028, depending on patent challenges and regulatory filings. Generic entry in Europe typically follows the U.S. market. Generic competition leads to substantial price erosion, typically reducing drug prices by 80-90% within the first year of availability.
• Competition from Verzenio and Kisqali: Eli Lilly's Verzenio and Novartis' Kisqali have continued to gain market share due to their broader approved indications (including early-stage breast cancer for both) and demonstrated survival benefits in various patient subsets. These drugs are expected to maintain or grow their market positions.
• Clinical Practice Evolution: Treatment guidelines and physician prescribing habits evolve based on new clinical data. The demonstrated benefits of newer CDK4/6 inhibitors in earlier lines of therapy or specific patient populations may influence IBRANCE's use.
• Oncology Drug Development: The continuous development of novel therapies in breast cancer, including antibody-drug conjugates (ADCs) and other targeted agents, may further fragment the market and impact IBRANCE's long-term positioning.
• Geographic Penetration: While established in major markets, there may be opportunities for further penetration in emerging markets, although pricing and access challenges will persist.

The market for IBRANCE is projected to experience a significant decline post-patent expiry. While it will likely retain some market share due to physician familiarity, established patient support, and potential specific niche uses, its revenue contribution will diminish considerably as generics enter and competitive therapies dominate.

Key Takeaways

• IBRANCE, a CDK4/6 inhibitor, achieved significant commercial success for Pfizer, reaching peak annual sales of approximately \$5.4 billion in 2020-2021.
• Its market exclusivity is primarily secured by a portfolio of compound, formulation, and method-of-use patents, with key U.S. patents facing expiry around late 2027/2028.
• Major regulatory approvals by the FDA and EMA formed the basis for its global market access, with expansion into male breast cancer and later lines of therapy broadening its utility.
• The competitive landscape is intense, with Eli Lilly's Verzenio and Novartis' Kisqali emerging as strong rivals, capturing market share through broader indications and superior survival data in select patient groups.
• The financial trajectory indicates a post-peak decline, with revenue dropping from \$5.4 billion in 2021 to \$4.9 billion in 2023, primarily due to increased competition.
• Future market projections anticipate a substantial revenue decrease following patent expiry due to generic competition and sustained pressure from existing and emerging therapeutic alternatives.

Frequently Asked Questions

1. When are the primary patents for IBRANCE expected to expire in the U.S.? The core U.S. patents protecting IBRANCE are expected to expire around late 2027 or 2028, though specific timelines can be affected by patent litigation and reviews.

2. Which competitors have had the most significant impact on IBRANCE's market share? Eli Lilly's Verzenio (abemaciclib) and Novartis' Kisqali (ribociclib) are the primary competitors that have impacted IBRANCE's market share, largely due to their expanded indications and demonstrated clinical benefits.

3. What is the typical price reduction observed after generic entry for oncology drugs like IBRANCE? Following generic entry, oncology drug prices typically experience reductions of 80-90% within the first year as multiple generic manufacturers compete.

4. Has IBRANCE received approval for any indications beyond metastatic breast cancer in postmenopausal women? Yes, IBRANCE has received approval for men with ER+/HER2- advanced or metastatic breast cancer and has been approved in combination with endocrine therapy.

5. What is the projected impact of generic entry on IBRANCE's annual revenue? Generic entry is projected to cause a substantial decrease in IBRANCE's annual revenue, diminishing its contribution as a blockbuster product to a fraction of its peak sales.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Approvals. Retrieved from [FDA Website] (Specific drug approval pages are accessed individually.)

[2] European Medicines Agency. (n.d.). European Public Assessment Reports (EPARs). Retrieved from [EMA Website] (Specific drug assessment reports are accessed individually.)

[3] Pfizer Inc. (2016-2023). Annual Reports. Retrieved from [Pfizer Investor Relations]

[4] Eli Lilly and Company. (2017-2023). Annual Reports. Retrieved from [Eli Lilly Investor Relations]

[5] Novartis AG. (2017-2023). Annual Reports. Retrieved from [Novartis Investor Relations]